Ionis Pharmaceuticals Tumbles on Biogen's Miss: Buy or Sell?
Ionis Pharmaceuticals (NASDAQ: IONS) lost 11% of its market value after commercialization partner Biogen (NASDAQ: BIIB) reported third-quarter sales of its drug, Spinraza, that failed to match industry watchers' forecasts. Is Ionis Pharmaceuticals' tumble a sign that investors should sell, or a buying opportunity?
Ionis Pharmaceuticals and Biogen are collaboration partners on Spinraza, a drug used to treat spinal muscular atrophy (SMA), a rare life-threatening disease.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
GSK plc ADR Stock
€36.00
-2.700%
With 6 Buy predictions and not the single Sell prediction the community is currently very high on GSK plc ADR.
With a target price of 49 € there is a positive potential of 36.11% for GSK plc ADR compared to the current price of 36.0 €.
